Is AstraZeneca plc A Super Income Stock?

Does AstraZeneca plc (LON: AZN) have the right credentials to be classed as a very attractive income play?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.


What a difference a year makes!

This time last year, the market was not particularly excited about the prospects for AstraZeneca (LSE: AZN) (NYSE: AZN.US). Not only were its earnings set to decline over the next few years, the company seemed to be doing little to arrest the decline in sales resulting from the patent expiry of a number of key drugs.

Fast forward one year and shares are 32% higher (versus a gain of 2.7% for the FTSE 100) and investors are optimistic about management’s ability to steer the company through the choppy waters of generic competition.

However, after the share price rise, is AstraZeneca still a super income stock?

A Strong Yield

Despite shares having a great year, they still yield an impressive 4.3%. This is considerably higher than the FTSE 100 yield of 3.5% and shows that AstraZeneca remains a highly attractive income play in the short run. However, with the company facing patent expiry (and subsequent generic competition) on a number of its key blockbuster drugs, dividends per share are forecast to flat line over the next two years. While this is disappointing, it’s a prudent move by management to ensure the long-term success of the company is not compromised.

A Well-Covered Dividend

Indeed, even with earnings per share (EPS) forecast to drop by 15% this year and by 2% in 2015, AstraZeneca’s dividend remains well-covered at over 1.5 times (meaning dividends can be paid 1.5 times with 2015’s net profit). This shows that, while the company is being generous with the proportion of earnings it pays out, it is ensuring that dividends remain at a sensible level, which is good news for the long-term health of the company (and for shareholders).


So, AstraZeneca offers a relatively attractive yield and looks to be on a solid path to recovery. Indeed, despite market sentiment improving (and the share price rising) it still looks inexpensive, relative to the wider market. AstraZeneca currently trades on a price to earnings (P/E) ratio of 13.2, which is slightly below that of the FTSE 100, which has a P/E of 13.5.

A Super Income Stock

Certainly, AstraZeneca’s P/E ratio will tick up over the next two years (as EPS falls) but when the quality of the company, its medium to long term prospects and its yield are all taken into account, it still looks good value. That’s why AstraZeneca remains a super income stock — especially for investors with a longer term outlook.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter owns shares in AstraZeneca.

More on Investing Articles

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

Buying 8,617 Legal & General shares would give me a stunning income of £1,840 a year

Legal & General shares offer one of the highest dividend yields on the entire FTSE 100. Harvey Jones wants to…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

£25k to invest? Here’s how I’d try to turn that into a second income of £12,578 a year!

If Harvey Jones had a lump sum to invest today he'd go flat out buying top FTSE 100 second income…

Read more »

Union Jack flag in a castle shaped sandcastle on a beautiful beach in brilliant sunshine
Investing Articles

2 lesser-known dividend stocks to consider this summer

Summer is here and global markets could be heading for a period of subdued trading. But our writer thinks there…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Here’s how I’d aim to build a £50K SIPP into a £250K retirement fund

Our writer outlines the approach he would take to try and increase the value of his SIPP multiple times in…

Read more »

Investing Articles

9.4%+ yields! 3 proven FTSE 100 dividend payers I’d buy for my Stocks and Shares ISA

Our writer highlights a trio of FTSE 100 shares with yields close to 10%. He'd happily pop them into his…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

Are Raspberry Pi shares a once-in-a-lifetime chance to get rich?

With Raspberry Pi shares surging after a successful IPO, could this UK tech startup offer a long-term wealth creation opportunity…

Read more »

Newspaper and direction sign with investment options
Investing Articles

Huge gains and 9% yields: why now’s an amazing time to be a stock market investor

The stock market’s generating fantastic returns in 2024. Whether you're looking for gains or income, it’s a great time to…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

This steady dividend payer looks like one of the best bargain stocks in the FTSE 100

A yield of 4.7% and a consistent dividend record make this FTSE 100 company look like good value in an…

Read more »